← Leaderboards
Michael Birrer
Clinical Sciences
$16,024,591
Attributed
$27,810,260
Total exposure
10
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $10.1M · FY2010–25$20M$15M$10M$5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$41,036,983 · 12
By mechanism
U01$19,255,449 · 3
P30$11,132,942 · 2
RC4$3,723,748 · 1
R01$3,604,394 · 2
U54$2,962,058 · 3
R21$358,392 · 1
Top collaborators
- Steven J Skates12 shared
- Amanda G Paulovich9 shared
- Samuel C Mok8 shared
- Ronny I Drapkin5 shared
- Upender Manne5 shared
- Isabel C Scarinci5 shared
- Sammy Ferri-Borgogno2 shared
Others in their field
Top investigators on “Malignant Neoplasm Of Ovary”
- David Heimbrook · Leidos Biomedical Research, Inc.$212,807,834
- Philip J Disaia · University Of California Irvine$127,836,851
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$32,228,202
- Larry Arthur$28,462,007
- Weiping Zou · University Of Michigan At Ann Arbor$24,295,958
- Robert C Bast · University Of Texas Md Anderson Can Ctr$22,987,143
Research focus
Malignant Neoplasm Of OvaryDiagnosisMalignant NeoplasmsWomanCancer CellBaseGenomicsNew Therapeutic TargetProteinsPathway InteractionsClinical TrialsGene ExpressionOvarian NeoplasmSignal TransductionTumorGrantTechnologySerousOperative Surgical ProceduresPathogenesisMolecularNovel TherapeuticsSpecimenOncogenes
Grant awards (82)
3D Spatial Multi-Omics Profiling of Ovarian Cancer$974,644
U01 · FY2025 · CA
3D Spatial Multi-Omics Profiling of Ovarian Cancer$1,004,570
U01 · FY2024 · CA
Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit$951,279
U01 · FY2021 · CA
Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit$811,228
U01 · FY2021 · CA
Proteomic, Genomic, and Longitudinal Pathways to Ovarian Cancer Biomarker Discovery$400,199
U01 · FY2021 · CA
Proteomic, Genomic, and Longitudinal Pathways to Ovarian Cancer Biomarker Discovery$82,995
U01 · FY2021 · CA
Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit$1
U01 · FY2021 · CA
Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit$1,423,336
U01 · FY2020 · CA
Proteomic, Genomic, and Longitudinal Pathways to Ovarian Cancer Biomarker Discovery$571,713
U01 · FY2020 · CA
Proteogenomic Studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit$440,000
U01 · FY2020 · CA
Admin-Core-001$206,996
U54 · FY2020 · CA
Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit$1,394,182
U01 · FY2019 · CA
Proteomic, Genomic, and Longitudinal Pathways to Ovarian Cancer Biomarker Discovery$594,149
U01 · FY2019 · CA
3/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership$206,996
U54 · FY2019 · CA
Admin-Core-001$206,996
U54 · FY2019 · CA
Validation of a genomic signature that predicts for sub-optimal debulking of epithelial ovarian cancer$96,018
R21 · FY2019 · CA · contact PI
Validation of a genomic signature that predicts for sub-optimal debulking of epithelial ovarian cancer$59,332
R21 · FY2019 · CA · contact PI
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT$5,104,077
P30 · FY2018 · CA · contact PI
Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit$1,441,604
U01 · FY2018 · CA
Proteomic, Genomic, and Longitudinal Pathways to Ovarian Cancer Biomarker Discovery$1,323,251
U01 · FY2018 · CA
3/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership$1,170,535
U54 · FY2018 · CA
Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit$440,000
U01 · FY2018 · CA
Validation of a genomic signature that predicts for sub-optimal debulking of epithelial ovarian cancer$203,042
R21 · FY2018 · CA · contact PI
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT$198,945
P30 · FY2018 · CA · contact PI
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT$91,218
P30 · FY2018 · CA · contact PI
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT$72,961
P30 · FY2018 · CA · contact PI
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT$52,084
P30 · FY2018 · CA · contact PI
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT$45,500
P30 · FY2018 · CA · contact PI
COMPREHENSIVE CANCER CENTER CORE SUPPORT GRANT$5,113,872
P30 · FY2017 · CA · contact PI
Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit$1,507,572
U01 · FY2017 · CA
Proteomic, Genomic, and Longitudinal Pathways to Ovarian Cancer Biomarker Discovery$1,356,082
U01 · FY2017 · CA
3/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership$1,170,535
U54 · FY2017 · CA
The FGF18/FGFR4 amplicon: Novel therapeutic biomarkers for ovarian cancer$226,535
R01 · FY2017 · CA · contact PI
The FGF18/FGFR4 amplicon: Novel therapeutic biomarkers for ovarian cancer$145,785
R01 · FY2017 · CA · contact PI
Proteomic, Genomic, and Longitudinal Pathways to Ovarian Cancer Biomarker Discovery$829,757
U01 · FY2016 · CA
The FGF18/FGFR4 amplicon: Novel therapeutic biomarkers for ovarian cancer$372,052
R01 · FY2016 · CA · contact PI
Gynecologic Cancers$93,366
P30 · FY2016 · CA · contact PI
The FGF18/FGFR4 amplicon: Novel therapeutic biomarkers for ovarian cancer$372,052
R01 · FY2015 · CA · contact PI
Gynecologic Cancers$93,399
P30 · FY2015 · CA · contact PI
Proteomic Genetic and Longitudinal Paths to Ovarian Cancer Biomarker Discovery$902,673
U01 · FY2014 · CA
The FGF18/FGFR4 amplicon: Novel therapeutic biomarkers for ovarian cancer$360,890
R01 · FY2014 · CA · contact PI
Novel Biomarkers in Ovarian Cancer$337,135
R01 · FY2014 · CA · contact PI
Gynecologic Cancers$88,496
P30 · FY2014 · CA · contact PI
Proteomic Genetic and Longitudinal Paths to Ovarian Cancer Biomarker Discovery$672,847
U01 · FY2013 · CA
The FGF18/FGFR4 amplicon: Novel therapeutic biomarkers for ovarian cancer$390,552
R01 · FY2013 · CA · contact PI
Novel Biomarkers in Ovarian Cancer$326,708
R01 · FY2013 · CA · contact PI
Gynecologic Cancers$85,643
P30 · FY2013 · CA · contact PI
Proteomic Genetic and Longitudinal Paths to Ovarian Cancer Biomarker Discovery$701,365
U01 · FY2012 · CA
Novel Biomarkers in Ovarian Cancer$347,562
R01 · FY2012 · CA · contact PI
Gynecologic Cancers$93,381
P30 · FY2012 · CA · contact PI
Proteomic Genetic and Longitudinal Paths to Ovarian Cancer Biomarker Discovery$720,550
U01 · FY2011 · CA
Novel Biomarkers in Ovarian Cancer$347,562
R01 · FY2011 · CA · contact PI
Genomic Stratification of Ovarian Cancer Patients$3,723,748
RC4 · FY2010 · CA · contact PI
Proteomic Genetic and Longitudinal Paths to Ovarian Cancer Biomarker Discovery$711,452
U01 · FY2010 · CA
Novel Biomarkers in Ovarian Cancer$377,561
R01 · FY2010 · CA · contact PI
The Molecular Genetics of Gynecologic Cancers$280,075
ZIA · FY2009 · CA · contact PI
The Use of Transcriptional Factors as Targets and Agents in Carcinogenesis$186,717
ZIA · FY2009 · CA · contact PI
The Molecular Genetics of Gynecologic Cancers$576,752
Z01 · FY2008 · CA · contact PI
The Use of Transcriptional Factors as Targets and Agents in Carcinogenesis$384,502
Z01 · FY2008 · CA · contact PI
The Molecular Genetics of Gynecologic Cancers$994,788
Z01 · FY2007 · CA · contact PI
The Use of Transcriptional Factors as Targets and Agents in Carcinogenesis$589,807
Z01 · FY2007 · CA · contact PI
The Molecular Genetics of Gynecologic Cancers$0
Z01 · FY2006 · SC · contact PI
The Molecular Mechanisms of Oncogene Action$0
Z01 · FY2006 · SC · contact PI
The Use of Transcriptional Factors as Targets and Agents$0
Z01 · FY2006 · SC · contact PI
The Molecular Mechanisms of Oncogene Action$0
Z01 · FY2005 · SC
The Molecular Genetics of Gynecologic Cancers$0
Z01 · FY2005 · SC
The Use of Transcriptional Factors as Targets and Agents$0
Z01 · FY2005 · SC
Transcriptional Factors as Targets and Agents in Carcin.$0
Z01 · FY2004 · SC
The Molecular Genetics of Gynecologic Cancers$0
Z01 · FY2004 · SC
The Molecular Mechanisms of Oncogene Action$0
Z01 · FY2004 · SC
The Molecular Mechanisms of Oncogene Action$0
Z01 · FY2003 · SC
The Molecular Genetics of Gynecologic Cancers$0
Z01 · FY2003 · SC
The Use of Transcriptional Factors as Targets and Agents$0
Z01 · FY2003 · SC
The Use of Transcriptional Factors as Targets and Agents$0
Z01 · FY2002 · SC
The Molecular Genetics of Gynecologic Cancers$0
Z01 · FY2002 · SC
The Molecular Mechanisms of Oncogene Action$0
Z01 · FY2002 · SC
Molecular Mechanisms of Oncogene Action$0
Z01 · FY2001 · SC
Molecular Genetics of Gynecologic Cancers$0
Z01 · FY2001 · SC
Use of Transcriptional Factors as Targets and Agents$0
Z01 · FY2001 · SC
The Molecular Mechanisms of Oncogene Action$0
Z01 · FY2000 · SC
The Use of Transcriptional Factors as Targets and Agents in Carcinogenesis$0
Z01 · FY2000 · SC
The Molecular Genetics of Gynecologic Cancers$0
Z01 · FY2000 · SC